SOUTH KOREA – Samsung Biologics has presented its latest achievements and strategic outlook for 2025 at the 43rd J.P. Morgan Healthcare Conference in San Francisco.
During the main track presentation, CEO and President John Rim highlighted the company’s continued growth and plans for the future, despite challenges in the industry.
He emphasized that Samsung Biologics is poised to enter a new phase of expansion, with the opening of Bio Campus II and the launch of antibody-drug conjugate (ADC) services.
“We’ll continue to invest in new modalities and technologies to better address client needs, maximizing satisfaction and ensuring the delivery of highest-quality products,” Rim stated.
Rim also reflected on the company’s remarkable performance in 2024, noting that Samsung Biologics had achieved its highest-ever annual results, with cumulative orders exceeding US $16.2 billion.
The company’s projected revenue growth for the year was between 15% and 20%. “This represents a nearly 15-fold increase compared to our revenue in 2016, the year of our initial public offering,” he added.
Samsung Biologics’ third-quarter revenue in 2024 amounted to 3.29 trillion won (US $2.2 billion), with operating profit reaching 994.4 billion won (US $681.3 million), marking significant growth of 26% and 30%, respectively, compared to the same period in 2023.
Rim outlined three strategic pillars that have supported the company’s growth: capacity expansion, portfolio diversification, and global presence.
As part of these plans, Samsung Biologics is set to complete its fifth plant by April 2025, which will add 180,000 liters of production capacity, marking the beginning of what Rim referred to as the “Second Bio Campus Era.”
The company is also contemplating the construction of a sixth plant, which could increase the total production capacity to 964,000 liters by 2027—a global record.
In addition to expanding capacity, Samsung Biologics plans to diversify its portfolio. By 2027, the company intends to enhance its capabilities in ADCs and establish automated pre-filled syringe (PFS) production facilities to meet the growing demand in Asia.
Rim also highlighted the company’s focus on expanding its international presence, with new sales offices planned for major bio hubs like Boston, New Jersey, and Tokyo.
“These efforts aim to boost engagement with major pharmaceutical companies and strengthen our position in the growing Asian market,” he said, noting that Japan is a key market for the company’s contract development and manufacturing services.
Further investment in cutting-edge technologies is a priority for Samsung Biologics, including expanding its services in ADCs and cell and gene therapies, such as adeno-associated viruses (AAV).
“By broadening our capabilities, we aim to address the increasing complexity of biopharmaceutical production and provide seamless solutions for our clients,” Rim explained.
Despite the challenges faced in the market, Rim expressed confidence in Samsung Biologics’ future.
“We are well-positioned to maintain our leadership through proactive investments and strategic initiatives,” he said.
He also noted that the company had secured a US $1.56 billion contract with a European pharmaceutical firm in early 2025, signaling a strong start to the year.
Looking ahead, Rim reiterated Samsung Biologics’ long-term vision, “Vision 2030,” which focuses on achieving global leadership as a top-tier biopharmaceutical company.
“Our work to achieve this vision revolves around our 4E strategy—Customer Excellence, Operational Excellence, Quality Excellence, and People Excellence,” he said.
Rim credited this framework for the company’s consistent performance, explaining that “4E guides every decision we make, from scaling our capacity to nurturing talent.“
XRP HEALTHCARE L.L.C | License Number: 2312867.01 | Dubai | © Copyright 2025 | All Rights Reserved